A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works

The basics of epithelial-mesenchymal transition

Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196 · see citing works

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · see citing works

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · see citing works

Cancer treatment and survivorship statistics, 2016

Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066 · see citing works

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · see citing works

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · see citing works

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025 · see citing works

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955 · see citing works

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545 · see citing works

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324 · see citing works

Non-small-cell lung cancers: a heterogeneous set of diseases

Chen, Z., Brainson, C. F., Hammerman, P. S., Kim, C. F., & Wong, K. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3775 · Cited by 1,935 · see citing works

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

Akbay, E. A., Koyama, S., Carretero, J., Altabef, A. B., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,237 · see citing works

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

Lynch, T. J., Bondarenko, I., Luft, A. V., Serwatowski, P., Barlési, F., Chacko, R. T., Sebastian, M., Neal, J. W., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 999 · see citing works

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

Chen, L., Gibbons, D. L., Goswami, S., Cortez, M. A., Ahn, Y., Byers, L. A., Zhang, X., Yi, X., Dwyer, D. W., Lin, W., et al. (2014) · Nature Communications · doi:10.1038/ncomms6241 · Cited by 972 · see citing works

The roles of TGFβ in the tumour microenvironment

Pickup, M. W., Novitskiy, S. V., & Moses, H. L. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3603 · Cited by 915 · see citing works

Cancer Metastasis Is Accelerated through Immunosuppression during Snail-Induced EMT of Cancer Cells

Kudo‐Saito, C., Shirako, H., Takeuchi, T., & Kawakami, Y. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.023 · Cited by 872 · see citing works

PDL1 Regulation by p53 via miR-34

Cortez, M. A., Ivan, C., Valdecanas, D., Wang, X., Peltier, H. J., Ye, Y., Araujo, L., Carbone, D. P., Shilo, K., Giri, D. K., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv303 · Cited by 683 · see citing works

B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression

Konishi, J. S., Yamazaki, K., Azuma, M., Kinoshita, I., Dosaka‐Akita, H., & Nishimura, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0428 · Cited by 678 · see citing works

Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis

Grünert, S., Jechlinger, M., & Beug, H. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1175 · Cited by 677 · see citing works

miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions

Siemens, H., Jackstadt, R., Hünten, S., Kaller, M., Menssen, A., Götz, U., & Hermeking, H. (2011) · Cell Cycle · doi:10.4161/cc.10.24.18552 · Cited by 607 · see citing works

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

Lahn, M. M. F., Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T., Cleverly, A., Desaiah, D., Guba, S. C., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s86621 · Cited by 558 · see citing works

An autocrine TGF-β/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition

Gregory, P. A., Bracken, C. P., Smith, E., Bert, A. G., Wright, J. A., Roslan, S., Morris, M. J., Belle, L., Farshid, G., Lim, Y., et al. (2011) · Molecular Biology of the Cell · doi:10.1091/mbc.e11-02-0103 · Cited by 552 · see citing works

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition

Mak, M. P., Tong, P., Diao, L., Cardnell, R. J., Gibbons, D. L., William, W. N., Skoulidis, F., Parra, E. R., Rodriguez‐Canales, J., Wistuba, I. I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0876 · Cited by 526 · see citing works

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

Boyerinas, B., Jochéms, C., Fantini, M. C., Heery, C. R., Gulley, J. L., Tsang, K. Y., & Schlom, J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0059 · Cited by 468 · see citing works

Interferon regulatory factor‐1 is prerequisite to the constitutive expression and IFN‐γ‐induced upregulation of B7‐H1 (CD274)

Lee, S. J., Jang, B., Lee, S.-W., Yang, Y., Suh, S., Park, Y.-M., Oh, S., Shin, J., Yao, S., Chen, L., et al. (2006) · FEBS Letters · doi:10.1016/j.febslet.2005.12.093 · Cited by 446 · see citing works

Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma

Lou, Y., Diao, L., Parra, E. R., Denning, W. L., Chen, L., Fan, Y. H., Byers, L. A., Wang, J., Papadimitrakopoulou, V. A., Behrens, C., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1434 · Cited by 439 · see citing works

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Strauss, J., Heery, C. R., Schlom, J., Madan, R. A., Cao, L., Kang, Z., Lamping, E., Marté, J. L., Donahue, R. N., Grenga, I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2653 · Cited by 406 · see citing works

A tale of two proteins: Differential roles and regulation of Smad2 and Smad3 in TGF‐β signaling

Brown, K. A., Pietenpol, J. A., & Moses, H. L. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21255 · Cited by 358 · see citing works

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

Heery, C. R., Coyne, G. O., Madan, R. A., Cordes, L. M., Rajan, A., Rauckhorst, M., Lamping, E., Oyelakin, I., Marté, J. L., Lepone, L. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30239-5 · Cited by 308 · see citing works

Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell–Mediated Lysis

Akalay, I., Janji, B., Hasmim, M., Noman, M. Z., André, F., de Crémoux, P., Bertheau, P., Badoual, C., Vielh, P. R., Larsen, A. K., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2432 · Cited by 302 · see citing works

Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells

Alsuliman, A., Çolak, D., Al‐Harazi, O., Fitwi, H., Tulbah, A. M., Al‐Tweigeri, T., Al-Alwan, M. M., & Ghebeh, H. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0421-2 · Cited by 288 · see citing works

TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer

Park, B. V., Freeman, Z. T., Ghasemzadeh, A., Chattergoon, M. A., Rutebemberwa, A., Steigner, J., Winter, M. E., Huynh, T. V., Sebald, S. M., Lee, S.-J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1347 · Cited by 287 · see citing works

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

Gulley, J. L., Rajan, A., Spigel, D. R., Iannotti, N. O., Chandler, J. C., Wong, D. J. L., Leach, J. W., Edenfield, W. J., Wang, D., Grote, H. J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30240-1 · Cited by 286 · see citing works

B7-H1 (Programmed Death-1 Ligand) on Dendritic Cells Is Involved in the Induction and Maintenance of T Cell Anergy

Selenko-Gebauer, N., Majdic, O., Szekeres, A., Höfler, G., Guthann, E., Korthäuer, U., Zlabinger, G. J., Steinberger, P., Pickl, W. F., Stockinger, H. S. J., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.7.3637 · Cited by 261 · see citing works

The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer

Zhao, L., Yu, H., Yi, S., Peng, X., Su, P., Xiao, Z., Liu, R., Tang, A., Li, X., Liu, F., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9659 · Cited by 227 · see citing works

MicroRNA-138 suppresses epithelial–mesenchymal transition in squamous cell carcinoma cell lines

Liu, X., Wang, C., Chen, Z., Jin, Y., Wang, Y., Kolokythas, A., Dai, Y., & Zhou, X. C. (2011) · Biochemical Journal · doi:10.1042/bj20111006 · Cited by 181 · see citing works

PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung

Kim, S., Koh, J., Kim, M., Kwon, D., Go, H., Kim, Y. A., Jeon, Y. K., & Chung, D. H. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.07.007 · Cited by 166 · see citing works

Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)

Shimoji, M., Shimizu, S., Sato, K., Suda, K., Kobayashi, Y., Tomizawa, K., Takemoto, T., & Mitsudomi, T. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.04.021 · Cited by 158 · see citing works

CCL2 is critical for immunosuppression to promote cancer metastasis

Kudo‐Saito, C., Shirako, H., Ohike, M., Tsukamoto, N., & Kawakami, Y. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9545-6 · Cited by 149 · see citing works

PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma

Ock, C.-Y., Kim, S., Keam, B., Kim, M., Kim, T. M., Kim, J.-H., Jeon, Y. K., Lee, J., Kwon, S. K., Hah, J. H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7431 · Cited by 146 · see citing works

Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).

Paz-Ares, L. G., Horn, L., Borghaei, H., Spigel, D. R., Steins, M. B., Ready, N., Chow, L. Q. M., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.18_suppl.lba109 · Cited by 146 · see citing works

MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer

Bouillez, A., Rajabi, H. N., Jin, C., Samur, M., Tagde, A., Alam, M., Hiraki, M., Maeda, T., Hu, X., Adeegbe, D. O., et al. (2017) · Oncogene · doi:10.1038/onc.2017.47 · Cited by 120 · see citing works

TGFβ-dependent expression of PD-1 and PD-L1 controls CD8+ T cell anergy in transplant tolerance

Baas, M. C., Besançon, A., Goncalves, T., Valette, F., Yagita∥, H., Sawitzki, B., Volk, H., Waeckel-Énée, E., Rocha, B., Chatenoud, L., et al. (2016) · eLife · doi:10.7554/elife.08133 · Cited by 116 · see citing works

Smad2 and Smad3 have differential sensitivity in relaying TGFβ signaling and inversely regulate early lineage specification

Liu, L., Liu, X., Ren, X., Tian, Y., Chen, Z., Xu, X., Du, Y., Jiang, C., Fang, Y., Liu, Z., et al. (2016) · Scientific Reports · doi:10.1038/srep21602 · Cited by 95 · see citing works

Dendritic cells with an increased PD-L1 by TGF-β induce T cell anergy for the cytotoxicity of hepatocellular carcinoma cells

Song, S., Yuan, P., Wu, H., Chen, J., Fu, J., Li, P., Lu, J., & Wei, W. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.02.027 · Cited by 84 · see citing works

WEE1 Inhibition Alleviates Resistance to Immune Attack of Tumor Cells Undergoing Epithelial–Mesenchymal Transition

Hamilton, D. H., Huang, B., Fernando, R. I., Tsang, K.-Y., & Palena, C. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1894 · Cited by 84 · see citing works

TGF-β of lung cancer microenvironment upregulates B7H1 and GITRL expression in dendritic cells and is associated with regulatory T cell generation

NI, X. Y., Sui, H. X., Liu, Y., Ke, S. Z., Wang, Y. N., & GAO, F. G. (2012) · Oncology Reports · doi:10.3892/or.2012.1822 · Cited by 79 · see citing works

Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation

Kurimoto, R., Iwasawa, S., Ebata, T., Ishiwata, T., Sekine, I., Tada, Y., Tatsumi, K., Koide, S., Iwama, A., & Takiguchi, Y. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3419 · Cited by 70 · see citing works

Targeting WNT1-inducible signaling pathway protein 2 alters human breast cancer cell susceptibility to specific lysis through regulation of KLF-4 and miR-7 expression

Akalay, I., Tan, T. Z., Kumar, P., et al. (2014) · Oncogene · doi:10.1038/onc.2014.151 · Cited by 65 · see citing works

MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition

David, J. M., Hamilton, D. H., & Palena, C. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1117738 · Cited by 65 · see citing works

An Autocrine Loop between TGF-β1 and the Transcription Factor Brachyury Controls the Transition of Human Carcinoma Cells into a Mesenchymal Phenotype

Larocca, C. A., Cohen, J. R., Fernando, R. I., Huang, B., Hamilton, D. H., & Palena, C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1007 · Cited by 64 · see citing works

Regulation of complement-dependent cytotoxicity by TGF-β-induced epithelial–mesenchymal transition

Goswami, M. T., Reka, A. K., Kurapati, H., et al. (2015) · Oncogene · doi:10.1038/onc.2015.258 · Cited by 55 · see citing works

Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types

Scognamiglio, G., Chiara, A. D., Bonito, M. D., Tatangelo, F., Losito, S., Anniciello, A., Cecio, R. D., D’Alterio, C., Scala, S., Cantile, M., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050790 · Cited by 43 · see citing works

TGF-Beta Treatment Modulates PD-L1 and CD40 Expression in Proximal Renal Tubular Epithelial Cells and Enhances CD8+ Cytotoxic T-Cell Responses

Starke, A., Wuthrich, R. P., & Waeckerle‐Men, Y. (2007) · Nephron Experimental Nephrology · doi:10.1159/000106506 · Cited by 36 · see citing works

Smad2 and Smad3 cooperate and antagonize simultaneously in vertebrate neurogenesis

Míguez, D. G., Gil-Guiñón, E., Pons, S., et al. (2013) · Journal of Cell Science · doi:10.1242/jcs.130435 · Cited by 28 · see citing works

Preliminary results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in advanced solid tumors.

Gulley, J. L., Heery, C. R., Schlom, J., Madan, R. A., Cao, L., Lamping, E., Marté, J. L., Cordes, L. M., Christensen, O., Helwig, C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3006 · Cited by 20 · see citing works

Pharmacological and immunological targeting of tumor mesenchymalization

David, J. M., Dominguez, C. L., & Palena, C. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.11.011 · Cited by 15 · see citing works

TGFβ biology in cancer progression and immunotherapy

Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944 · see citing works

Regulation of PD-L1 expression in the tumor microenvironment

Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01027-5 · Cited by 681 · see citing works

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Strauss, J., Heery, C. R., Schlom, J., Madan, R. A., Cao, L., Kang, Z., Lamping, E., Marté, J. L., Donahue, R. N., Grenga, I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2653 · Cited by 406 · see citing works

Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion

Jiang, Y., & Zhan, H. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.10.013 · Cited by 319 · see citing works

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances

Lind, H., Gameiro, S. R., Jochems, C., Donahue, R. N., Strauss, J., Gulley, J. L., Palena, C., & Schlom, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000433 · Cited by 247 · see citing works

M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine

Knudson, K. M., Hicks, K. C., Luo, X., Chen, J.-Q., Schlom, J., & Gameiro, S. R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1426519 · Cited by 195 · see citing works

<p>Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor</p>

Bai, X., Yi, M., Jiao, Y., Chu, Q., & Wu, K. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s224013 · Cited by 153 · see citing works

Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-β

Metelli, A., Wu, B. X., Riesenberg, B., Guglietta, S., Huck, J. D., Mills, C., Li, A., Rachidi, S., Krieg, C., Rubinstein, M. P., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay4860 · Cited by 139 · see citing works

Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms

Huang, M.-Y., Jiang, X.-M., Wang, B.-L., Sun, Y., & Lu, J.-J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107694 · Cited by 136 · see citing works

Integrin αvβ8–expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells

Takasaka, N., Seed, R. I., Cormier, A., Bondesson, A. J., Lou, J., Elattma, A., Ito, S., Yanagisawa, H., Hashimoto, M., Ma, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122591 · Cited by 119 · see citing works

The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial

Metropulos, A. E., Munshi, H. G., & Principe, D. R. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104380 · Cited by 81 · see citing works

Correction: Effects of the support on bifunctional one-step synthesis of methylal via methanol oxidation catalysed by Fe–Mo-based bifunctional catalysts

Yuan, M. J., Tang, R., Sun, X., et al. (2022) · Sustainable Energy & Fuels · doi:10.1039/d2se90063g

Determination of bifunctional compounds. Part IV. 4-iodobutaneboronic acid as a selective reagent for the trace determination of bifunctional compounds

(1979) · doi:10.1039/an9790400082 · Cited by 17 · see citing works

A bifunctional luminescent europium–organic framework for highly selective sensing of nitrobenzene and 4-aminophenol

(2017) · doi:10.1039/c7ra08885j · Cited by 26 · see citing works

Coupling rules for bifunctional pair sites

(2023) · doi:10.1016/j.matt.2022.12.005 · Cited by 5 · see citing works

Autoxidation of mercaptans promoted by a bifunctional catalyst

(1977) · doi:10.1016/0304-5102(77)80040-0 · Cited by 78 · see citing works